Category: Greatbatch Inc.
Greatbatch merges its sales, marketing and operations with subsidiary Electrochem in the interest of shifting from sub-assemblies to complete medical devices, raising its 2013 per-share earnings guidance.
Texas medical device maker Greatbatch (NYSE:GB) raised its 2013 per-share earnings guidance as it announced new efforts to reorganize some of its business practices and reduce costs as it shifts from a components and sub-assemblies company to a developer of full medical devices.
Edwards Lifesciences CEO Michael Mussallem updates investors on U.S. sales expectations for its flagship Sapien heart valve and says the end might be near for its long legal battle with Medtronic's CoreValve over transcatheter aortic valve implant patents covering Sapien.
Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.
Greatbatch's increases 22% during its 3rd quarter, but the medical device maker posts net losses of $ 7.6 million in due to operational issues at its Swiss facilities.
Medical device maker Greatbatch (NYSE:GB) lost $7.6 million in 3Q, the result of the nearly $15 million in expense to close a pair of Swiss factories.
Sunshine Heart shares close up just shy of 14% on news of CE Mark approval for its C-Pulse outside-the-bloodstream heart pump in the European Union.
Sunshine Heart (ASX:SHC) is shining on Wall Street today after announcing European regulatory approval for its C-Pulse heart assist system, with SHC shares closing up nearly 14% on the news.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Greatbatch, blaming a slumping orthopedics market and downward pricing pressure from customers, proposes to lay off 90% of its workers at 2 plants in Switzerland, aiming to relocate most of the operations to Indiana and Mexico.
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.